EP12.01. Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Ying Liu
Meta Tag
Speaker Ying Liu
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
Asian patients
stage IV non-small cell lung cancer
third-generation tyrosine kinase inhibitor
EGFR subtype
FLAURA trial
EGFR L858R mutation
first-line treatment
second-generation TKIs
survival benefit
Powered By